Acute Respiratory Infection Consortium
NCT01021098 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2018
Last updated 2023-11-24
Summary
Recently, the emergence and rapid global dissemination of novel swine-origin influenza A virus (H1N1) with unique epidemiologic characteristics has heightened awareness and concern of this viral pathogen, and its potential for major disruption of both civil and military stability. Although advances in medical and scientific technologies have improved our basic understanding of respiratory disease, many questions about the epidemiology and immunology of ARI remain unanswered. This study plans to initiate a multi-site, multi-disciplinary research collaboration, termed the Acute Respiratory Infection Consortium (ARIC) for the purpose of studying the etiology, epidemiology and immunology of influenza-like illness (ILI) in order to describe the natural history and risk factors for disease, as well as the characteristics of the host immune response.
At the core of the ARIC is the proposed observational, longitudinal study of the Natural History Study of ILI among active duty military members, healthy retirees, and their dependents recruited from both inpatient and outpatient settings of military treatment facilities (MTF) in the continental US to be followed for a total of four (4) visits over a 28-day period. Additionally, the investigators also propose to conduct a household-based study of influenza (Family Transmission Study) in which individuals who have a laboratory-confirmed influenza illness will be recruited and enrolled along with their family members for the purpose of studying transmission of influenza within households. Taken together, these studies will establish a longitudinal cohort of ILI among active duty members and their families, as well as a repository of biological specimens relevant to the epidemiology and immunology of infection. Ultimately, these studies will serve as a solid foundation on which future investigations of ARI epidemiology, treatment and prevention can be based.
Conditions
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Henry M. Jackson Foundation for the Advancement of Military Medicine
lead OTHER
Principal Investigators
-
Timothy H Burgess, MD, MPH · Uniformed Services University of the Health Sciences/Infectious Disease Clinical Research Program
Eligibility
- Min Age
- 17 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-11-30
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- United States
Study Locations
More Related Trials
-
Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza
NCT01011582 ·Status: COMPLETED
-
Self-Administered Nasal Influenza Feasibility Study
NCT01933048 ·Status: COMPLETED ·Phase: PHASE4
-
Nontypeable H. Influenzae in Healthy Adults
NCT00905385 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
NCT00783926 ·Status: COMPLETED ·Phase: PHASE1
-
Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
NCT06848309 ·Status: RECRUITING
-
Study of the Safety and Immunogenicity of H1N1 Vaccine
NCT01177202 ·Status: COMPLETED ·Phase: PHASE1
-
H7N9 Boost in Healthy Adults
NCT02586792 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)
NCT01024673 ·Status: COMPLETED
-
Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally
NCT00489931 ·Status: COMPLETED ·Phase: PHASE1
-
2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies
NCT01270685 ·Status: WITHDRAWN
-
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
NCT00800605 ·Status: COMPLETED ·Phase: PHASE3
-
Severe Influenza Cohort
NCT02392858 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.
NCT01262079 ·Status: COMPLETED
-
Do Some Healthy Adults Consistently Have Systemic Reactions to Influenza Vaccines?
NCT02263027 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
NCT01052480 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
NCT02572817 ·Status: COMPLETED ·Phase: PHASE3
-
Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months
NCT00996307 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers
NCT02594189 ·Status: COMPLETED ·Phase: PHASE1
-
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
NCT04794829 ·Status: RECRUITING
-
Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups
NCT00711295 ·Status: COMPLETED ·Phase: PHASE3
-
A Retrospective, Observational Registry of Participants With Avian Influenza Infection
NCT02743676 ·Status: COMPLETED
-
H9 Priming Study in Healthy Adults
NCT00617331 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years
NCT01560793 ·Status: COMPLETED ·Phase: PHASE1
-
The Human Mucosal Immune Responses to Influenza Virus (SLVP026)
NCT03023553 ·Status: COMPLETED ·Phase: PHASE4
-
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
NCT03232567 ·Status: COMPLETED ·Phase: PHASE2